Literature DB >> 19913826

Patient perceived effectiveness of a new male sling as treatment for post-prostatectomy incontinence.

Bradley C Gill1, Mia A Swartz, John B Klein, Raymond R Rackley, Drogo K Montague, Sandip P Vasavada, Kenneth W Angermeier.   

Abstract

PURPOSE: Objective measures show the AdVance() sling provides some benefit in post-prostatectomy incontinence. To our knowledge no validated, patient determined outcomes have been used to assess this procedure. We described the patient perceived effectiveness and postoperative complications.
MATERIALS AND METHODS: A retrospective chart review was followed by a telephone survey consisting of the Patient Global Impression of Improvement, Patient Global Impression of Severity, and questions about recommending the surgery, daily pad use and complications. Successful outcomes were Patient Global Impression of Improvement responses of very much better or much better without further incontinence treatment. Objective success is defined as pad-free or a reduction to 2 or less pads daily.
RESULTS: A total of 35 patients received the sling a median of 25 months after prostatectomy. Telephone surveys were administered a mean of 35 weeks after the sling procedure and 33 patients were contacted. Of the cases 18 (51.4%) and 21 (60%) were patient determined and objective successes, respectively. Of the patients with subjective treatment failure 3 would recommend the surgery to a friend and 12 were undecided or would not. Furthermore, no patients with subjective treatment failure were pad-free and 10 (58.8%) had pads that were mostly wet on changing. For the entire population a reduction in median daily pad use from 2.5 to 1 was observed as well as a strong association (p <0.01) between Patient Global Impression of Improvement and Patient Global Impression of Severity responses. Three individuals pursued further treatment with bulking agents and 3 had retention that resolved.
CONCLUSIONS: The AdVance sling is safe, and demonstrates similar subjective and objective outcomes. The procedure can benefit some individuals with post-prostatectomy incontinence and, therefore, may be another treatment option for this condition.

Entities:  

Mesh:

Year:  2010        PMID: 19913826     DOI: 10.1016/j.juro.2009.08.159

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  7 in total

1.  Risk factors of treatment failure after retrourethral transobturator male sling.

Authors:  Irina Soljanik; Christian Gozzi; Armin J Becker; Christian G Stief; Ricarda M Bauer
Journal:  World J Urol       Date:  2011-03-18       Impact factor: 4.226

2.  The impact of prior urethral sling on artificial urinary sphincter outcomes.

Authors:  Matthew J Ziegelmann; Brian J Linder; Marcelino E Rivera; Boyd R Viers; Daniel S Elliott
Journal:  Can Urol Assoc J       Date:  2016 Nov-Dec       Impact factor: 1.862

Review 3.  [Therapy of male urinary incontinence: artificial sphincter versus male slings].

Authors:  W Leicht; J Thüroff
Journal:  Urologe A       Date:  2012-03       Impact factor: 0.639

4.  The retrourethral transobturator sling suspension in the treatment of male urinary stress incontinence: results of a single institution experience.

Authors:  Johannes Mueller; Andres Jan Schrader; Thomas Schnoeller; Friedemann Zengerling; Ilija Damjanoski; Andreas Al Ghazal; Mark Schrader; Florian Jentzmik
Journal:  ISRN Urol       Date:  2012-05-17

5.  Current trends in the management of post-prostatectomy incontinence.

Authors:  Joon Chul Kim; Kang Jun Cho
Journal:  Korean J Urol       Date:  2012-08-16

Review 6.  Male incontinence and the transobturator approach: An analysis of current outcomes.

Authors:  Salvatore Siracusano; Francesco Visalli; Laura Toffoli
Journal:  Arab J Urol       Date:  2013-09-29

Review 7.  Hypothesis That Urethral Bulb (Corpus Spongiosum) Plays an Active Role in Male Urinary Continence.

Authors:  Peter Rehder; Nina M Staudacher; Joerg Schachtner; Maria E Berger; Florian Schillfahrt; Verena Hauser; Raphael Mueller; Viktor Skradski; Wolfgang Horninger; Bernhard Glodny
Journal:  Adv Urol       Date:  2016-01-31
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.